An interventional study of MRD-Guided Maintenance Discontinuation and Active Surveillance in MRD-Guided Maintenance for Multiple Myeloma in Latin America, sponsored by Hospital Universitario Dr. Jose E. Gonzalez. Not yet recruiting. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-11-19.
Sponsored by Hospital Universitario Dr. Jose E. Gonzalez · Not applicable, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
This prospective, pragmatic, multicenter study aims to evaluate the clinical and quality-of-life outcomes of discontinuing maintenance therapy in newly diagnosed MM patients with sustained MRD negativity for two years. By implementing a structured active surveillance strategy with serial MRD and QoL assessments, this study seeks to determine whether treatment-free intervals can be safely achieved without compromising survival outcomes, while improving patient well-being and reducing financial burden.
If successful, this study will provide foundational evidence to support MRD-guided, individualized maintenance strategies in MM and will serve as a platform for future interventional trials in Latin America.
Multiple myeloma is a blood cancer that can require long-term maintenance treatment, even after a very good response to initial therapy. Although maintenance treatment can help control the disease, continuing it for many years may cause side effects, affect quality of life, and create financial burdens. Measurable residual disease (MRD) testing can detect very small amounts of myeloma cells that may remain after treatment.
This prospective, multicenter study in Latin America will evaluate a strategy of stopping maintenance therapy in selected adults with newly diagnosed multiple myeloma who have achieved a complete or stringent complete response and have remained MRD-negative for at least two consecutive years while receiving maintenance therapy.
After maintenance therapy is discontinued, participants will be followed for 24 months through clinical assessments, MRD testing, and quality-of-life questionnaires every six months. Maintenance therapy will be restarted if MRD reappears or if clinical or biochemical criteria for disease relapse are met, according to the study protocol.
The main objective is to evaluate whether this strategy can be implemented safely and to measure the occurrence of MRD reappearance, disease relapse, or death within 24 months. Additional objectives include evaluating progression-free survival, overall survival, quality of life, time until maintenance therapy is restarted, and the feasibility of this approach across Latin American centers.
The study aims to generate evidence to help guide individualized maintenance treatment decisions for selected patients with multiple myeloma.
3,764 studies on the registry are indexed under Multiple Myeloma; 768 are open to participants now.
This study's planned enrollment of 62 is above the median of 41 across 3,008 interventional studies indexed under Multiple Myeloma.
Browse Multiple Myeloma studies →Hospital Universitario Dr. Jose E. Gonzalez is the lead sponsor of 84 studies on the registry; 13 are open to participants now.
Counted across the registry records on this site, refreshed daily.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
A line of therapy is one course of treatment, which may combine several drugs. First-line is the first course given; second-line follows when that stops working or is not tolerated.
“Two prior lines” means two courses that count separately under the study’s rules — not simply two drugs. Ask the study team if you are unsure how yours are counted.
Stem cell (bone marrow) transplants. Allogeneic uses cells from a donor; autologous uses your own cells, collected earlier and given back.
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Line of therapy
A line of therapy is one course of treatment, which may combine several drugs. First-line is the first course given; second-line follows when that stops working or is not tolerated.
“Two prior lines” means two courses that count separately under the study’s rules — not simply two drugs. Ask the study team if you are unsure how yours are counted.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Allogeneic and autologous transplant
Stem cell (bone marrow) transplants. Allogeneic uses cells from a donor; autologous uses your own cells, collected earlier and given back.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ECOG performance status
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Eligible participants will discontinue maintenance therapy after meeting the protocol-defined criteria, including sustained measurable residual disease (MRD) negativity for at least two consecutive years and no evidence of active disease on PET/CT. Participants will undergo active surveillance for 24 months, with clinical assessments, MRD testing, and health-related quality-of-life evaluations every six months. If MRD reappears or clinical or biochemical disease relapse criteria are met, maintenance therapy will be reinitiated according to the study protocol. All participants will receive the same intervention strategy, as this is a single-arm study.
Other: MRD-Guided Maintenance Discontinuation and Active Surveillance
The intervention consists of discontinuing maintenance therapy in selected adults with newly diagnosed multiple myeloma who have achieved complete response or stringent complete response and sustained measurable residual disease (MRD) negativity for at least two consecutive years during maintenance therapy, with no evidence of active disease on PET/CT. Following discontinuation, participants will undergo active surveillance for 24 months, with clinical assessments, bone marrow MRD testing, and health-related quality-of-life evaluations every six months. MRD will be assessed using next-generation flow cytometry. Maintenance therapy will be reinitiated if MRD reappears or if clinical or biochemical disease relapse criteria are met, according to the study protocol. The strategy is evaluated prospectively in a single-arm, multicenter study across Latin America.
Strategy Failure Rate at 24 Months Following MRD-Guided Maintenance Discontinuation
Strategy failure is defined as the first occurrence of any of the following events after maintenance discontinuation: (1) measurable residual disease (MRD) resurgence, defined as conversion from sustained MRD negativity to MRD positivity detected by next-generation flow cytometry (EuroFlow; sensitivity ≥10\^-5); (2) clinical or biochemical relapse/progression according to IMWG criteria; or (3) death from any cause. The outcome will be measured as the proportion of participants experiencing at least one strategy failure event.
Time frame: From maintenance discontinuation (baseline) through 24 months.
Measurable Residual Disease-Free Survival (MRD-FS)
Time from maintenance discontinuation to the first occurrence of MRD resurgence or death from any cause. MRD will be assessed using next-generation flow cytometry (EuroFlow; sensitivity ≥10\^-5). MRD-FS will be estimated using the Kaplan-Meier method.
Time frame: From maintenance discontinuation through 24 months.
Treatment-Free Survival (TFS)
Time from maintenance discontinuation to re-initiation of maintenance therapy or death from any cause, whichever occurs first. TFS will be estimated using the Kaplan-Meier method.
Time frame: From maintenance discontinuation through 24 months.
Progression-Free Survival (PFS)
Time from maintenance discontinuation to documented clinical or biochemical disease progression according to IMWG criteria or death from any cause, whichever occurs first. PFS will be estimated using the Kaplan-Meier method.
Time frame: From maintenance discontinuation through 24 months.
Overall Survival (OS)
Time from maintenance discontinuation to death from any cause. Overall survival will be estimated using the Kaplan-Meier method, with survival probabilities reported at 12 and 24 months.
Time frame: From maintenance discontinuation through 24 months.
Measurable Residual Disease (MRD) Resurgence Rate
Proportion of participants who convert from sustained MRD negativity to MRD positivity during follow-up, assessed by next-generation flow cytometry (EuroFlow; sensitivity ≥10\^-5).
Time frame: At months 6, 12, 18, and 24 after maintenance discontinuation.
Time to Maintenance Therapy Re-initiation
Time from maintenance discontinuation to the re-initiation of maintenance therapy, regardless of whether treatment is restarted due to MRD resurgence, clinical or biochemical relapse, or investigator discretion.
Time frame: From maintenance discontinuation through 24 months.
Change From Baseline in Health-Related Quality of Life Assessed by EORTC QLQ-C30
Changes in health-related quality of life will be assessed using the EORTC QLQ-C30 questionnaire.
Time frame: Baseline and months 6, 12, 18, and 24.
Change From Baseline in Multiple Myeloma-Specific Quality of Life Assessed by EORTC QLQ-MY20
Changes in multiple myeloma-specific health-related quality of life will be assessed using the EORTC QLQ-MY20 questionnaire.
Time frame: Baseline and months 6, 12, 18, and 24.
No study locations are listed for this record.
Start is estimated for Nov 2026; primary completion for Nov 2028, 24 months later.
Of 172 non-industry interventional studies with no phase under Multiple Myeloma, half reached primary completion within 37 months of starting (the median), counting those still running; a quarter within 21 and three quarters within 81. This study's planned 24 months is below that.
Counting every sponsor, half of 186 studies reached it within 38 months; a quarter within 20 and three quarters within 79.
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
This study is not yet recruiting, as verified in Oct 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Hospital Universitario Dr. Jose E. Gonzalez